SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    CoQ10 and vascular function: dilation is a surrogate endpoint

    An eight-week trial found improved flow-mediated dilation in ischemic heart dysfunction. It did not establish fewer clinical events or directly prove a nitric-oxide mechanism.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    What the study found

    Fifty-six people with ischemic left-ventricular systolic dysfunction were randomized to CoQ10 or placebo. Researchers measured brachial flow-mediated dilation and a lactate-to-pyruvate ratio used as a mitochondrial-function indicator. [1]

    The CoQ10 group improved on those measures. Blood pressure, lipids, glucose measures and several inflammatory or oxidative markers did not significantly change relative to controls. [1]

    What remains unanswered

    A vascular response measurement is not the same as measuring nitric-oxide production directly, and correlated marker changes do not prove a causal pathway. The trial did not establish reduced heart attacks or mortality. Funding and conflicts were not established from the abstract. [1]

    A hypothetical distinction

    Imagine two markers improve together. One may help explain the other, but their correlation does not establish that changing the first caused the second.

    Evidence summary — CoQ10 and vascular function
    DetailInterpretation
    56 patientsSpecific heart condition
    Flow-mediated dilationSurrogate result
    Clinical eventsNot established
    CoQ10 and vascular function: dilation is a surrogate endpoint — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial - PubMed
      Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.